Jordan Cater

Jordan Cater

Auto-generated profile, based on publicly available information

Jordan Cater

University of Wollongong

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
JCJordan H. Cater
Jordan H. Cater
NSNehad S. El Salamouni
Nehad S. El Salamouni
GMGhada H. Mansour
Ghada H. Mansour
SHSebastian Hutchinson
Sebastian Hutchinson
CGConall Mc Guinness
Conall Mc Guinness
LSLisanne M. Spenkelink
Lisanne M. Spenkelink
Quenchbodies, antibodies labelled with fluorophores that increase in intensity upon antigen binding, offer great promise for biosensor development. Nanobody-based quenchbodies are particularly attractive due to their small size, ease of expression, high stability, rapid evolvability, and amenability to protein engineering. However, existing designs for protein detection show limited dynamic range, with fluorescence increases of only 1.1–1.4 fold. Here we identify the tryptophan residues in the nanobody complementarity-determining regions (CDRs) that are critical to quenchbody performance. Using a combination of rational design and molecular dynamics simulations, we developed an optimised nanobody scaffold with tryptophans introduced at key positions. We used this scaffold in an in vitro directed-evolution screen against human inflammatory cytokine interleukin-6 (IL-6). This yielded quenchbodies with 1.5–2.4-fold fluorescence increases, enabling IL-6 detection down to 1–2 nM. Our scaffold provides a valuable platform for developing biosensors for diverse protein targets, with applications in research, diagnostics, and environmental monitoring.

29 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
JCJordan H. Cater
Jordan H. Cater
NMNoralyn Basco Manucat-Tan
Noralyn Basco Manucat-Tan
DGDemi Kay Georgiou
Demi Kay Georgiou
GZGuomao Zhao
Guomao Zhao
IBIrina A. Buhimschi
Irina A. Buhimschi
MRMarie Ranson
Marie Ranson
Plasminogen activator inhibitor type-2 (PAI-2), a member of the serpin family, is dramatically upregulated during pregnancy and in response to inflammation. Although PAI-2 exists in glycosylated and non-glycosylated forms in vivo, the majority of in vitro studies of PAI-2 have exclusively involved the intracellular non-glycosylated form. This study shows that exposure to inflammation-associated hypochlorite induces the oligomerisation of PAI-2 via a mechanism involving dityrosine formation. Compared to plasminogen activator inhibitor type-1 (PAI-1), both forms of PAI-2 are more resistant to hypochlorite-induced inactivation of its protease inhibitory activity. Holdase-type extracellular chaperone activity plays a putative non-canonical role for PAI-2. Our data demonstrate that glycosylated PAI-2 more efficiently inhibits the aggregation of Alzheimer’s disease and preeclampsia-associated amyloid beta peptide (Aβ), compared to non-glycosylated PAI-2 in vitro. However, hypochlorite-induced modification of non-glycosylated PAI-2 dramatically enhances its holdase activity by promoting the formation of very high-molecular-mass chaperone-active PAI-2 oligomers. Both PAI-2 forms protect against Aβ-induced cytotoxicity in the SH-SY5Y neuroblastoma cell line in vitro. In the villous placenta, PAI-2 is localised primarily to syncytiotrophoblast with wide interpersonal variation in women with preeclampsia and in gestational-age-matched controls. Although intracellular PAI-2 and Aβ staining localised to different placental cell types, some PAI-2 co-localised with Aβ in the extracellular plaque-like aggregated deposits abundant in preeclamptic placenta. Thus, PAI-2 potentially contributes to controlling aberrant fibrinolysis and the accumulation of misfolded proteins in states characterised by oxidative and proteostasis stress, such as in Alzheimer’s disease and preeclampsia.

27 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJordan Harry Cater
Jordan Harry Cater
NENehad Elsalamouny
Nehad Elsalamouny
GMGhada H. Mansour
Ghada H. Mansour
SHSebastian Hutchinson
Sebastian Hutchinson
CGConall Mc Guinness
Conall Mc Guinness
NSNehad S. El Salamouni
Nehad S. El Salamouni
Quenchbodies are antibodies labelled with a fluorophore that increases in intensity upon antigen binding, which makes them promising candidates for the development of diagnostic or other immunoassays requiring antigen quantification. Quenchbodies based on camelid nanobodies are particularly attractive for rapid development of immunoassays against molecular antigens of interest, due to their small size, ease of expression, high stability, rapid evolvability, and amenability to protein engineering. However, current nanobody-based quenchbodies typically display only modest fluorescence increases when binding to protein antigens (≤ 1.1–1.7-fold), with few examples reaching > 2-fold. In contrast to single-chain variable region (scFv; 32 kDa) or antigen-binding fragment (Fab; 50 kDa) quenchbodies, where semi-conserved tryptophans at the VH-VL interface quench the fluorophore, here we show that tryptophan residues in the nanobody complementarity-determining regions (CDRs) are critical to fluorescence antigen detection. This informed the development of a synthetic convex-binding nanobody library containing conserved tryptophans in the CDRs, which was used for the in vitro selection and affinity maturation of novel quenchbodies against human inflammatory cytokine interleukin 6 (IL6). Initial in silico modelling and biochemical analyses showed that existing nanobodies for maltose-binding protein (MBP) and lysozyme could be converted into quenchbodies (Qb-MBP and Qb-Lys), with fluorescence fold-increases of 1.5 and 1.3, respectively, when recognising their cognate antigen. Rational mutational substitution of tryptophans into the CDR-region of the quenchbodies resulted in fluorescence fold-increases of 1.9 and 1.6 for Qb-MBP (Y59W/Y114W) and Qb-Lys (Y110W), respectively, supporting the importance of CDR-based tryptophans in the nanobody quenchbody mechanism. A synthetic nanobody library containing conserved CDR-based tryptophans was then created, selected, and affinity matured using a completely in vitro SNAP-display system, yielding quenchbodies against interleukin-6 (IL6) with enhanced fluorescence fold-increases of 1.5–2.4 (EC50 = 20–1,113 nM binding affinity). The ease and speed by which nanobody-based quenchbodies can be discovered using this completely in vitro selection strategy based on a single synthetic library, makes this a very attractive approach to develop immunoassays for detection of a wide range of molecular targets, including proteins.

27 May 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
NSNehad El Salamouni
Nehad El Salamouni
JCJordan Cater
Jordan Cater
LSLisanne Spenkelink
Lisanne Spenkelink
HYHaibo Yu
Haibo Yu
Nanobodies, the smallest functional antibody fragment derived from camelid heavy-chain-only antibodies, have emerged as powerful tools for diverse biomedical applications. In this comprehensive review, we discuss the structural characteristics, functional properties, and computational approaches driving the design and optimisation of synthetic nanobodies. We explore their unique antigen-binding domains, highlighting the critical role of complementarity-determining regions in target recognition and specificity. This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen-binding mechanisms and conformational dynamics. Finally, we examine a direct example of how computational design strategies were implemented for improving a nanobody-based immunosensor, known as a Quenchbody. Through combining experimental findings and computational insights, this review elucidates the transformative impact of nanobodies in biotechnology and biomedical research, offering a roadmap for future advancements and applications in healthcare and diagnostics.

27 November 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
NSNehad El Salamouni
Nehad El Salamouni
JCJordan Cater
Jordan Cater
QZQiang Zhu
Qiang Zhu
LSLisanne Spenkelink
Lisanne Spenkelink
HYHaibo Yu
Haibo Yu
Nanobody-based quenchbodies are emerging as powerful tools for the sensitive and specific detection of biomolecular targets. These fluorescent sensors contain tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker. Upon antigen binding the fluorophore is displaced, resulting in an increase in intensity. Recent quenchbodies developed against the inflammatory cytokine interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding. To investigate the molecular basis of this discrepancy, we combined data-driven structural prediction with physics-based molecular dynamics simulations. Using a benchmark dataset of nanobody–lysozyme complexes, we first established that HelixFold3 provides more accurate structural predictions than AlphaFold3. Leveraging this finding, we used HelixFold3 to model the structures of the IL6-binding quenchbodies. Our analyses revealed that poor responders exhibit solvent-exposed tryptophan residues upon antigen binding, notably tryptophan 110, allowing fluorophore quenching and reduced fluorescence. In contrast, good responders adopt conformations in which these tryptophan residues are largely buried, resulting in a more pronounced fluorescence increase upon antigen binding. Together, these results illustrate that integrating structural predictions with molecular dynamics simulations offer a powerful framework for decoding quenchbody mechanisms and advancing the rational development of highly responsive fluorescent sensors.